Ivermectin as a Novel Therapy in COVID-19 Treatment

July 29, 2021 updated by: Sherief Abd-Elsalam, Tanta University

The Efficacy of Ivermectin in COVID-19 Treatment

Efficacy of Ivermectin in COVID-19 treatment

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Clinical Study Evaluating the Efficacy of Ivermectin in COVID-19 treatment

Study Type

Interventional

Enrollment (Actual)

164

Phase

  • Phase 2
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Tanta, Egypt
        • Sherief Abd-Elsalam

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • All Adult Patients aging from 20 to 65 years-old with COVID-19 confirmed by pharyngeal swab PCR.

Exclusion Criteria:

  • Allergy or contraindication to the drugs used in the study.
  • Pregnant and lactating mothers.
  • Patients with cardiac problems.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Ivermectin
Ivermectin plus standard of care treatment Dose 2 tablets 12mg per day for 3 days
Drug: Ivermectin
Ivermectin treatment
Other Names:
  • iverzine, ivermectin
No Intervention: Standard of care
Standard of care treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The number of patients with mortality
Time Frame: 1 month
Improvement of survival
1 month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Length of hospital stay
Time Frame: 1 month
Effect on the length of hospital stay
1 month
The need for mechanical ventilation
Time Frame: 1 month
Need for mechanical ventilation
1 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Tanta University

Investigators

  • Principal Investigator: sherief Abd-Elsalam, Ass. Prof., ass. Prof. Tropical Medicine

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2020

Primary Completion (Actual)

October 31, 2020

Study Completion (Actual)

December 1, 2020

Study Registration Dates

First Submitted

May 23, 2020

First Submitted That Met QC Criteria

May 23, 2020

First Posted (Actual)

May 27, 2020

Study Record Updates

Last Update Posted (Actual)

August 2, 2021

Last Update Submitted That Met QC Criteria

July 29, 2021

Last Verified

July 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • tanta covid treatment

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on COVID

Clinical Trials on Ivermectin

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe